Sector: Health care
US_ABBV
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: yahoo_fundamentals_timeseries/ABBV
Monetary columns are in B USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueB USD | Operating profitB USD | D&AB USD | EBITDAB USD | Net profitB USD | Operating CFB USD | Capex + M&AB USD | AssetsB USD | EquityB USD | ROE (annualized) | Net debtB USD | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Q1 2026 (3M) | OK | 15.0 y/y 12.4% | 4.0 y/y 6.9% | 1.9 y/y -5.1% | 5.9 y/y 2.7% | 0.7 y/y -46.0% | 3.8 | -0.3 | 136.5 y/y 0.2% | -6.7 y/y -568.7% | -56.0% | 55.1 | Link |
| 2025-12-31 | Q4 2025 (3M) | OK | 16.6 y/y 10.0% | 4.5 y/y 405.0% | 1.9 y/y -10.1% | 6.5 y/y 899.4% | 1.8 y/y 8354.5% | 5.2 | -0.3 | 134.0 y/y -0.9% | -3.3 y/y -198.3% | -143.0% | 57.1 | Link |
| 2025-09-30 | Q3 2025 (3M) | OK | 15.8 y/y 9.1% | 1.9 y/y -50.3% | 2.1 y/y 0.0% | 4.0 y/y -32.5% | 0.2 y/y -88.1% | 7.0 | -0.4 | 133.9 y/y -6.6% | -2.6 y/y -143.8% | -17.6% | 61.1 | Link |
| 2025-06-30 | Q2 2025 (3M) | OK | 15.4 y/y 6.6% | 4.9 y/y 22.4% | 2.1 y/y 0.1% | 7.0 y/y 14.8% | 0.9 y/y -31.5% | 5.2 | -0.3 | 137.2 y/y -3.4% | -0.2 y/y -102.7% | 606.6% | 62.0 | Link |
| 2025-03-31 | Q1 2025 (3M) | OK | 13.3 y/y 8.4% | 3.7 y/y 33.4% | 2.0 y/y -1.7% | 5.8 y/y 18.5% | 1.3 y/y -6.1% | 1.6 | -0.4 | 136.2 y/y -8.5% | 1.4 y/y -82.3% | 216.8% | 60.9 | Link |
| 2024-12-31 | Q4 2024 (3M) | OK | 15.1 y/y 5.6% | -1.5 y/y -146.6% | 2.1 y/y 2.5% | 0.6 y/y -87.7% | 0.0 y/y -102.7% | 7.0 | -0.3 | 135.2 y/y 0.3% | 3.3 y/y -67.9% | 91.4% | 55.7 | Link |
| 2024-09-30 | Q3 2024 (3M) | OK | 14.5 y/y 3.8% | 3.8 y/y 68.0% | 2.1 y/y -4.8% | 5.9 y/y 32.3% | 1.6 y/y -12.2% | 5.4 | -8.5 | 143.4 y/y 5.3% | 6.0 y/y -50.1% | 32.5% | 51.2 | Link |
| 2024-06-30 | Q2 2024 (3M) | OK | 14.5 y/y 4.3% | 4.0 y/y -11.4% | 2.1 y/y -9.0% | 6.1 y/y -10.6% | 1.4 y/y -32.3% | 2.3 | -0.2 | 141.9 y/y 4.9% | 6.8 y/y -47.3% | 74.1% | 44.9 | Link |
| 2024-03-31 | Q1 2024 (3M) | OK | 12.3 y/y 0.7% | 2.8 y/y 1.1% | 2.1 y/y -2.5% | 4.9 y/y -0.5% | 1.4 y/y 472.8% | 4.0 | -9.4 | 148.9 y/y 10.7% | 8.0 y/y -39.7% | 59.6% | 45.7 | Link |
| 2023-12-31 | Q4 2023 (3M) | OK | 14.3 y/y — | 3.2 y/y — | 2.1 y/y — | 5.3 y/y — | 0.8 y/y — | 4.8 | -0.2 | 134.7 y/y — | 10.4 y/y — | 43.3% | 40.3 | Link |
| 2023-09-30 | Q3 2023 (3M) | OK | 13.9 y/y — | 2.3 y/y — | 2.2 y/y — | 4.5 y/y — | 1.8 y/y — | 7.6 | -0.2 | 136.2 y/y — | 12.1 y/y — | 19.0% | 42.3 | Link |
| 2023-06-30 | Q2 2023 (3M) | OK | 13.9 y/y — | 4.5 y/y — | 2.3 y/y — | 6.8 y/y — | 2.0 y/y — | 6.3 | -0.2 | 135.4 y/y — | 12.9 y/y — | 61.9% | 47.0 | Link |
| 2023-03-31 | Q1 2023 (3M) | OK | 12.2 y/y — | 2.8 y/y — | 2.1 y/y — | 4.9 y/y — | 0.2 y/y — | 4.2 | -0.2 | 134.5 y/y — | 13.3 y/y — | — | 52.6 | Link |
Quarterly values ($ mln)
Year-over-year change
FCF ($ mln)
Net debt / cash ($ mln)
Value the company creates per year, as a % of market cap
Value created per year: +5.7%
| 1. EBITDA growth (latest quarter YoY, annualised) [EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-03-31 vs 2025-03-31) = (5 926 − 5 772) × 3.95 | 609 |
| 2. Current EV/EBITDA (LTM) (Market cap + Net debt) ÷ EBITDA (LTM) = (455 519 + 55 141) ÷ 23 433 | 21.8x |
| 3. Target multiple (Current EV/EBITDA + 12) ÷ 2 = (21.8 + 12) ÷ 2 | 16.9x |
| 4. Cash flow (balance method, LTM) Net-debt reduction + dividends + buybacks − equity issuance = 5 803 + 8 907 + 1 505 − 0 | 16 215 |
| 4b. Share dilution (at market, LTM) Share-count growth over the year × Market cap = 0.1% × 455 519 | −514 |
| 5. Value created per year (EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap = (609 × 16.9 + 16 215 − 514) ÷ 455 519 | +5.7% |
Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.
Caveats:
Current 21.5x · 3-year average 21.2x
| Date | Per share | Details | Status | Source |
|---|---|---|---|---|
| 2026-07-15 | 1.73 USD | Ex-dividend: 1.73 USD per share | Paid | Yahoo Finance (ex-div) |
| 2026-04-15 | 1.73 USD | Ex-dividend: 1.73 USD per share | Paid | Yahoo Finance (ex-div) |
| 2026-01-16 | 1.73 USD | Ex-dividend: 1.73 USD per share | Paid | Yahoo Finance (ex-div) |
| 2025-10-15 | 1.64 USD | Ex-dividend: 1.64 USD per share | Paid | Yahoo Finance (ex-div) |
| 2025-07-15 | 1.64 USD | Ex-dividend: 1.64 USD per share | Paid | Yahoo Finance (ex-div) |
| 2025-04-15 | 1.64 USD | Ex-dividend: 1.64 USD per share | Paid | Yahoo Finance (ex-div) |
| 2025-01-15 | 1.64 USD | Ex-dividend: 1.64 USD per share | Paid | Yahoo Finance (ex-div) |
| 2024-10-15 | 1.55 USD | Ex-dividend: 1.55 USD per share | Paid | Yahoo Finance (ex-div) |
| 2024-07-15 | 1.55 USD | Ex-dividend: 1.55 USD per share | Paid | Yahoo Finance (ex-div) |
| 2024-04-12 | 1.55 USD | Ex-dividend: 1.55 USD per share | Paid | Yahoo Finance (ex-div) |
| 2024-01-12 | 1.55 USD | Ex-dividend: 1.55 USD per share | Paid | Yahoo Finance (ex-div) |
| 2023-10-12 | 1.48 USD | Ex-dividend: 1.48 USD per share | Paid | Yahoo Finance (ex-div) |
| 2023-07-13 | 1.48 USD | Ex-dividend: 1.48 USD per share | Paid | Yahoo Finance (ex-div) |
| 2023-04-13 | 1.48 USD | Ex-dividend: 1.48 USD per share | Paid | Yahoo Finance (ex-div) |
| 2023-01-12 | 1.48 USD | Ex-dividend: 1.48 USD per share | Paid | Yahoo Finance (ex-div) |
| 2022-10-13 | 1.41 USD | Ex-dividend: 1.41 USD per share | Paid | Yahoo Finance (ex-div) |
| 2022-07-14 | 1.41 USD | Ex-dividend: 1.41 USD per share | Paid | Yahoo Finance (ex-div) |
| 2022-04-13 | 1.41 USD | Ex-dividend: 1.41 USD per share | Paid | Yahoo Finance (ex-div) |
| 2022-01-13 | 1.41 USD | Ex-dividend: 1.41 USD per share | Paid | Yahoo Finance (ex-div) |
| 2021-10-14 | 1.3 USD | Ex-dividend: 1.3 USD per share | Paid | Yahoo Finance (ex-div) |
KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)
Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of AbbVie Inc. — from primary filings.
Biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics.